

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: **Babu et al.**

Application No.: **Not Yet Assigned**

Group Art Unit: **Not Yet Assigned**

Filed: **April 2, 2004**

Examiner: **Not Yet Assigned**

For: **FLUOROQUINOLONE FORMULATIONS AND METHODS OF MAKING
AND USING THE SAME**

Date: April 2, 2004

MAIL STOP PATENT APPLICATION

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Sir:

Attached is a list of documents on Form PTO-1449, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the waiver by the U.S. Patent and Trademark Office of requirements under 37 C.F.R. § 1.98(a)(2)(i) for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC § 371 after June 30, 2003.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.56 and Section 609 of the MPEP. No fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

Respectfully submitted,


Kenneth D. Sibley
Registration No. 31,665


Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428
Raleigh, North Carolina 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401
Customer No. 20792

CERTIFICATE OF EXPRESS MAILING

"Express Mail" mailing label number: EY381443129 US

Date of Deposit: 4/2/2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450


Lindsey D. Hall, CP
Certified Paralegal

Substitute form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	Not Yet Assigned
Filing Date	April 2, 2004
First Named Inventor	Babu et al.
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	9244-12

U.S. PATENTS AND PATENT PUBLICATIONS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
		4,844,902		Grohe	07-04-1989
		6,284,804		Singh et al.	09-04-2001
		6,359,016		Singh et al.	03-19-2002
		6,569,443		Dawson et al.	05-27-2003
		6,395,746		Cagle et al.	05-28-2002
		6,239,113		Dawson et al.	05-29-2001
		5,814,638		Lee et al.	09-29-1998
		20030206956		Dawson et al.	11-06-2003
		20030143259		Roy et al.	07-31-2003
		20020022629		Cagle et al.	02-21-2002
		2003027790		Singh et al.	02-06-2003
		2002198174		Lyons	12-26-2002
		20010049366		Singh et al.	12-06-2001
		6,333,045		Yasueda et al.	12-25-2001
		6,509,327		Cagle et al.	01-21-2003
		5,855,916		Chiesi et al.	01-05-1999

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
		Office	Number	Kind Code (if known)			
		WO	00/01365		Leo Pharmaceutical Products Ltd.	01-13-2000	
		WO	89/09057		Alcon Laboratories, Inc.	10-05-1989	
		WO	90/01933		Alcon Laboratories, Inc.	03-08-1990	
		WO	03/072141		Pharmacia Corporation	09-04-2003	
		WO	02/39993		Chandavarkar et al.	05-23-2002	

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
		<i>CIPRO® I.V. (ciprofloxacin) For Intravenous Infusion (Bayer Corp. 2002)</i>	
		<i>Ciloxan® (ciprofloxacin HCl ophthalmic solution) (Alcon Labs 2003)</i>	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.